CLEVIPREX® (clevidipine) Low-volume dosing for rapid BP control

Consider CLEVIPREX (clevidipine) for low-volume dosing

Considerations to mitigate risk of excessive fluid intake

When fluid overload may be a concern, CLEVIPREX is a low-volume dosing option for reduction of BP1

Excessive fluid intake may lead to adverse outcomes in critically ill patients2,3

The ECLIPSE trial (see safety data) was comprised of 3 parallel, prospective, randomized, open-label studies that compared the safety and efficacy of CLEVIPREX (n=752) to active comparators: nitroglycerin (n=278) and sodium nitroprusside (n=283) in the perioperative setting, or nicardipine (n=193) in the postoperative setting. Safety was the primary endpoint (defined as the incidence of death, MI, stroke, or renal dysfunction at 30 days). The study was not powered for noninferiority or superiority.4

CLEVIPREX was not studied or proven to impact fluid overload.

Low-volume and non–weight-based dosing available in ready-to-use vials1

Consider Low-Volume Dosing for Reduction of BP With CLEVIPREX when fluid overload may be a concernConsider Low-Volume Dosing for Reduction of BP With CLEVIPREX when fluid overload may be a concern

*Most patients will achieve the desired therapeutic response at approximately 4 to 6 mg/h.1

Low-volume dosing with CLEVIPREX1

Watch a video featuring Dr. Solomon Aronson, lead investigator of the ECLIPSE trials, as he discusses the trials and how CLEVIPREX was studied against active comparators. Learn how CLEVIPREX drug administration compared with nicardipine in the postoperative setting.

(9:59)

BP control was similar across treatments in the ECLIPSE trials4

AUC=area under the curve.
*Post hoc analysis of mITT population.
†P<0.05 vs comparator(s).

CLEVIPREX was similar to nicardipine in maintaining patients within a prespecified BP range

Efficacy was a secondary endpoint and was assessed by measuring the magnitude and duration of BP excursions above or below a predefined SBP range vs comparators.

Serious AEs were reported by day 7 or discharge4


CLEVIPREX (n=752) All Comparators (n=754) Patients with ≥1 serious AEAtrial fibrillation Respiratory failure Acute renal failure Ventricular fibrillation Cardiac arrest Cerebrovascular accident Postprocedural hemorrhage 17.7% 20.0% L 2.4% 1.1%2.3% 0.9% 0.5%0.5%0.5% 2.4% 2.5%1.7%1.5%1.1%1.1%1.1%
  • AEs observed within 1 hour of the end of infusion were similar between patients who received CLEVIPREX and those who received comparators1
  • Incidence of AEs leading to study drug discontinuation: CLEVIPREX=5.9%; all active comparators=3.2%1
  • No AEs were >2% more common with CLEVIPREX than the average of all the comparators1

View Additional Safety Results From the ECLIPSE Trials

Drug administration in the ECLIPSE trials4


show icon  Show quartiles

hide icon  Hide quartiles
Dosing in the ECLIPSE trials was based on patient weight, whereas the dosing described in the Prescribing Information is not weight-based. However, the actual doses administered to patients in these trials and recommended by the Prescribing Information are similar. The data in the left column only represents 1 of the 3 ECLIPSE trials.1,4

*Based on the availability of IV nicardipine at the time of ECLIPSE, nicardipine concentration was most likely 0.1 mg/mL.

Median average infusion rate was 4x lower with CLEVIPREX than nicardipine4*

*Adapted from the ECLIPSE trial safety population data. Data presented are observational and should not be overinterpreted.

Proven efficacy in clinical studies1,5-8

CLEVIPREX provided BP reduction in a range of patients and various clinical settings.

Explore the Clinical Studies

Proven efficacy in clinical studies1,5-8

CLEVIPREX provided BP reduction in a range of patients and various clinical settings.

Explore the Clinical Studies

CLEVIPREX videos for healthcare professionals

Get access to videos about CLEVIPREX presented by renowned anesthesiologist Dr. Todd Horowitz and view other resources.

WATCH VIDEOS

CLEVIPREX videos for healthcare professionals

Get access to videos about CLEVIPREX presented by renowned anesthesiologist Dr. Todd Horowitz and view other resources.

WATCH VIDEOS

Transitioning off CLEVIPREX

Learn what to consider when transitioning patients off CLEVIPREX.
Treatment Transitioning